OPTIMIZE-1 Primary Analysis: Safety, Efficacy and Biomarker Results of a Phase 1b/2 Study Combining CD40 Agonist Mitazalimab with Mfolfirinox in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Mpdac).